Q-Med AB: Invitation to Interim Report Conference Call January-September 2008

Regulatory News:

Q-Med (STO:QMED):

Time: Thursday, October 24, 2008 at 10.00 a.m. CET.

To join the conference:
Swedish dial in number: + 46 (0)8 505 201 10
UK dial in number: +44 (0)20 7162 0025

Q-Med participants:
Bengt Ågerup, President and CEO
Alexander Kotsinas, Vice President and CFO
Madelene Sandgren, Director Investor Relations and Corporate Communications

The press release for Q-Med AB’s interim report will be released approximately 08.00 a.m on October 24, 2008.

The slide presentation will be available at: www.q-med.com/Investors/Presentations

A recorded version of the presentation will be available for seven working days on tel: +44 (0)20 7031 4064, access code: 81 34 11.

Queries should be addressed to:
Madelene Sandgren,
Director Investor Relations and Corporate Communications,
Tel: + 46 (0)70 974 90 15

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden.
Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01.
E-mail: info@q-med.com.
Web: www.q-med.com.

In USA, Q-Med AB’s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

This information was brought to you by Cision http://www.cisionwire.com